PI use has been associated with adverse changes in lipoproteins, endothelial dysfunction, and increased cardiovascular disease risk. This study evaluated changes in endothelial function, lipoproteins, and cardiovascular inflammatory markers in hyperlipidemic, atazanavir (ATV) -naive PI-experienced patients who switched their PI to ATV, a PI with a favorable lipid profile.

Endothelial Function, Lipoproteins,and Cardiovascular Inflammatory Markers in Treated HIV-infected Patients with Hyperlipidemia Who Were Switched to an Atazanavir-containing Regimen or Continued on Other Protease Inhibitor-based Therapy: Switch to Atazanavir and Brachial Artery Reactivity Study / R., Murphy; C., Zala; B., Berzins; C., Fichtenbaum; M., Dube; Guaraldi, Giovanni; F., Torriani; E., Belsey; C., Mitchell; J., Stein; SABAR Study, Team. - STAMPA. - not applicable:(2009), pp. 325 (#722)-325. (Intervento presentato al convegno 16th Conference on Retroviruses and Opportunistic Infections tenutosi a Montreal, Canada nel Feb 8-11, 2009).

Endothelial Function, Lipoproteins,and Cardiovascular Inflammatory Markers in Treated HIV-infected Patients with Hyperlipidemia Who Were Switched to an Atazanavir-containing Regimen or Continued on Other Protease Inhibitor-based Therapy: Switch to Atazanavir and Brachial Artery Reactivity Study

GUARALDI, Giovanni;
2009

Abstract

PI use has been associated with adverse changes in lipoproteins, endothelial dysfunction, and increased cardiovascular disease risk. This study evaluated changes in endothelial function, lipoproteins, and cardiovascular inflammatory markers in hyperlipidemic, atazanavir (ATV) -naive PI-experienced patients who switched their PI to ATV, a PI with a favorable lipid profile.
2009
16th Conference on Retroviruses and Opportunistic Infections
Montreal, Canada
Feb 8-11, 2009
R., Murphy; C., Zala; B., Berzins; C., Fichtenbaum; M., Dube; Guaraldi, Giovanni; F., Torriani; E., Belsey; C., Mitchell; J., Stein; SABAR Study, Team
Endothelial Function, Lipoproteins,and Cardiovascular Inflammatory Markers in Treated HIV-infected Patients with Hyperlipidemia Who Were Switched to an Atazanavir-containing Regimen or Continued on Other Protease Inhibitor-based Therapy: Switch to Atazanavir and Brachial Artery Reactivity Study / R., Murphy; C., Zala; B., Berzins; C., Fichtenbaum; M., Dube; Guaraldi, Giovanni; F., Torriani; E., Belsey; C., Mitchell; J., Stein; SABAR Study, Team. - STAMPA. - not applicable:(2009), pp. 325 (#722)-325. (Intervento presentato al convegno 16th Conference on Retroviruses and Opportunistic Infections tenutosi a Montreal, Canada nel Feb 8-11, 2009).
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/595988
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact